Related Experiment Videos
Experience with subcutaneous erythropoietin in CAPD patients
G R Bailie1, R Plitnick, G Eisele
1Albany College of Pharmacy, New York.
Summary
Subcutaneous erythropoietin (EPO) effectively increased hematocrit in patients on continuous ambulatory peritoneal dialysis (CAPD). This anemia treatment reduced transfusion needs without significant changes in iron levels or blood pressure.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Anemia is a common complication in patients undergoing chronic peritoneal dialysis.
- Erythropoiesis-stimulating agents are used to manage anemia in chronic kidney disease.
Purpose of the Study:
- To evaluate the efficacy and safety of subcutaneous erythropoietin (EPO) in patients on continuous ambulatory peritoneal dialysis (CAPD).
Main Methods:
- 18 CAPD patients received subcutaneous EPO (initial dose 157.6 U/kg/wk) and oral iron supplements.
- Hematocrit, iron parameters, transfusion requirements, and blood pressure were monitored.
Main Results:
- All patients responded to EPO, with a mean hematocrit increase of 47%.
- Hematocrit reached a steady state (34.1%) in 11 patients.
- Transfusion requirements decreased significantly from 0.42 to 0.22 units/patient/month.
- No significant changes in iron parameters or blood pressure were observed.
Conclusions:
- Subcutaneous EPO is an effective treatment for anemia in CAPD patients.
- EPO therapy improves hematocrit and reduces transfusion dependency.
- The treatment is well-tolerated with minimal side effects.